Form 4: Artivion CCO Reports Routine Stock Transactions

Artivion's Chief Commercial Officer, John E. Davis, reported sales of shares for tax obligations and a new restricted stock grant.

Summary

• John E. Davis, Chief Commercial Officer of ARTIVION, INC. (AORT), reported transactions involving the company's common stock.
• On February 23, 2026, Mr. Davis sold 3,773 shares of common stock at a price of $37.588 per share.
• This sale was executed to satisfy tax withholding obligations upon the vesting of performance stock units and was a non-discretionary 'sell to cover' transaction.
• On February 24, 2026, an additional 2,075 shares of common stock were sold at $35.693 per share.
• This second sale also served to cover tax withholding obligations related to the vesting of restricted stock units and was non-discretionary.
• Following these sales, Mr. Davis's direct beneficial ownership stood at 188,868 shares.
• On February 24, 2026, Mr. Davis acquired 20,438 shares of restricted stock at a price of $0.
• These newly acquired restricted shares will vest at a rate of 33 1/3% per year, commencing on the first anniversary of the grant date, under the company's Equity and Cash Incentive Plan.
• After all reported transactions, Mr. Davis's direct beneficial ownership increased to 209,306 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The sales were non-discretionary for tax purposes, and the new restricted stock grant is a standard compensation event, neither of which suggests a significant shift in company outlook or executive confidence.

Positives

• The acquisition of 20,438 shares of restricted stock at a $0 price indicates a new equity grant to the Chief Commercial Officer, aligning management's interests with long-term shareholder value.
• The vesting schedule of 33 1/3% per year over three years provides a retention incentive for a key executive.

Future Outlook

The filing indicates future vesting events for the newly granted restricted stock, with 33 1/3% of the 20,438 shares vesting annually starting one year from the grant date.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures required by the SEC. They provide transparency into executive stock ownership and compensation, which is a standard practice across all publicly traded companies in the medical technology and healthcare sectors, similar to peers like Medtronic or Edwards Lifesciences, though the specific details are company-specific.

Comparison to Industry Standards

• The 'sell to cover' transactions for tax withholding are a common practice for executives receiving equity compensation across all industries, including medical devices, and are not indicative of discretionary selling.
• Equity grants, such as the restricted stock units received by Mr. Davis, are a standard component of executive compensation packages designed to align management incentives with shareholder interests, consistent with practices at comparable companies in the S&P 500.

Stakeholder Impact

• Shareholders: The transactions are routine and primarily related to executive compensation and tax obligations, with minimal direct impact on the company's operational or financial performance. The new equity grant aligns executive incentives with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The newly acquired 20,438 shares of restricted stock will vest 33 1/3% per year, beginning on the first anniversary of the grant date.

Key Dates

Keywords

ARTIVION, AORT, Form 4, Insider Transaction, Stock Sale, Restricted Stock, Performance Stock Units, Equity Grant, Chief Commercial Officer, Tax Withholding